Quantum-Si incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QSI research report →
Range $1.9 – $4
Price Chart
About the company
Quantum-Si incorporated operates within the life sciences sector, focusing on the creation of an advanced platform for individual molecule detection. This innovative technology is designed to streamline sample preparation and subsequent sequencing processes. The company offers a unique, proprietary single molecule detection system that draws on advancements from the semiconductor industry.
- CEO
- Jeffrey Alan Hawkins
- IPO
- 2020
- Employees
- 145
- HQ
- Branford, CT, US
Get TickerSpark's AI analysis on QSI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $181.62M
- P/E
- -2.56
- PEG
- -0.04
- P/S
- 159.53
- P/B
- 1.38
- EV/EBITDA
- -2.02
- Div Yield
- 0.00%
- Gross Margin
- 34.94%
- Op Margin
- -7474.47%
- Net Margin
- -6729.80%
- ROE
- -44.72%
- ROIC
- -57.90%
Latest fiscal year · YoY change
- Revenue
- $2.44M-20.3%
- Gross Profit
- $1.15M-27.9%
- Op Income
- $-97,360,000
- Net Income
- $-101,339,000-0.3%
- EPS
- $-0.51+28.2%
- OCF Growth
- -7.9%
- FCF Growth
- -5.3%
- 52W High
- $1.81
- 52W Low
- $0.69
- 50D MA
- $1.16
- 200D MA
- $0.96
- Beta
- 3.25
- RSI (14)
- 43
- Avg Volume
- 6.86M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Quantum-Si said Proteus remains on track for a Q2 2027 launch, with instrument variability largely addressed, 19 amino acids demonstrated, and a preorder program now underway.· November 5, 2026
- Proteus development is progressing: design activities are complete, major components are released and ordered, and first instruments from the current build cycle are expected this quarter.
- Management said instrument variability issues have been "substantially addressed" and that performance data, including World HUPO, increased confidence in the architecture.
- The company has demonstrated detection of 19 amino acids and believes it is well positioned to show the 20th before year-end, which it sees as important for launch.
- Commercial preparation is accelerating: the company completed more than 35 roadshow events across the U.S., Canada and Europe and launched a Proteus preorder program.
- Full-year 2026 guidance was lowered for adjusted operating expenses and cash usage, reflecting cost discipline and restructuring savings while protecting launch readiness.
Third-quarter 2026 revenue was $212,000 versus $552,000 in the third quarter of 2025. Revenue for the first 9 months of 2026 was $814,000 versus $2 million in the prior-year period. Gross profit was $74,000 with gross margin of 35% in the quarter; for the first 9 months, gross profit was $320,000 with gross margin of 39%. GAAP total operating expenses were $23.9 million in Q3 2026 versus $40 million a year ago; adjusted operating expenses were $18.2 million versus $21.4 million. Net loss was $22.3 million versus $35.7 million, and adjusted EBITDA was negative $17 million versus negative $20.1 million. Cash, cash equivalents and investments were $149.4 million at September 30, 2026. For full-year 2026, the company reiterated revenue guidance of approximately $1 million, lowered adjusted operating expense guidance to $87 million or less from $98 million or less, and lowered total cash usage guidance to $87 million or less from $93 million or less. Management said it continues to expect approximately $12 million in annualized operating expense savings from the restructuring.
Jeff Hawkins framed the quarter around three priorities: improving Proteus, preparing the market, and preserving financial strength. He emphasized that the additional instrument design cycle is complete, performance has improved materially, and the company is on track for a second-quarter 2027 commercial launch. He also highlighted progress on 19 amino acids, the push toward 20, new AI/ML analysis work, and library preparation innovations that could expand Proteus applications and support a path to reference-free sequencing in 2027.
Jeff Keyes focused on the financial bridge to launch and the balance between spending discipline and readiness. He cited Q3 revenue of $212,000, gross margin of 35%, adjusted operating expenses of $18.2 million, and cash of $149.4 million, saying the company believes it has sufficient capital to fund operations into the fourth quarter of 2028. He said restructuring actions are now implemented, are delivering intended savings, and are expected to reduce annualized operating expense by about $12 million. He also noted supply-chain actions may modestly increase near-term working capital, but management does not expect them to jeopardize a Q2 2027 launch.
Analysts pressed management on preorder versus early access, and Hawkins said preorder is a broad program that can give customers preferred pricing and priority in line for early access or launch shipments. Questions also centered on whether the World HUPO data reflects launch specs; management said launch will have defined specifications, but the current data is not the fully optimized final product and they expect upside from here to launch. On commercialization, Hawkins said the early funnel is split fairly evenly between existing Platinum Pro users and de novo customers, and he said the main education hurdle is helping buyers understand that Proteus is a step-change, not just more wells. Management also said it does not expect a major sales-force ramp before launch, and Keyes said the supply-chain work is about getting ahead of longer lead times, not changing the launch timeline.
The company is showing concrete technical progress, including 19 amino acids, improving instrument consistency, and stronger data from the integrated units and World HUPO. Management sounded increasingly confident in both the platform and the launch path, with a preorder program, growing customer engagement, and a Q2 2027 launch still intact. They also said the cash position and cost cuts give them runway into late 2028, reducing near-term financing pressure.
Current revenue remains very small and fell year over year, underscoring that Quantum-Si is still in a development and market-prep phase rather than a commercial scale-up. The company is still working through instrument development, supply-chain complexity, and the final step of demonstrating the 20th amino acid before year-end. Management also signaled that launch metrics are not yet final and that some customer adoption will depend on early access data and sample-specific results, which leaves execution risk between now and commercialization.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.1%
- Shares Outstanding
- 199.80M
- Float Shares
- 171.99M
of shares held by institutions
148 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 9.61M | ▲ 892.51K |
| Vanguard Capital Management LLC | 7.51M | ▼ 68.08K |
| Ark Investment Management LLC | 7.39M | ▲ 225.28K |
| Blackrock, Inc. | 4.79M | ▼ 435.69K |
| Amova Asset Management Americas, Inc. | 3.71M | ▼ 171.80K |
| Sumitomo Mitsui Trust Group, Inc. | 3.71M | ▼ 171.80K |
| Geode Capital Management, LLC | 2.13M | ▼ 111.01K |
| Susquehanna International Group, Llp | 1.88M | ▲ 758.56K |
| Ubs Group AG | 1.35M | ▼ 1.21M |
| Renaissance Technologies LLC | 1.20M | ▲ 642.65K |
| Vanguard Fiduciary Trust Co | 1.12M | 0 |
| State Street Corp | 790.94K | ▼ 99.80K |
Held by 73 ETFs
Biggest fund positions in QSI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 21, 26 | Hawkins Jeffrey Alan | sell | 20,143 |
| Sep 22, 26 | Hawkins Jeffrey Alan | sell | 9,709 |
| Sep 21, 26 | Keyes Jeffry R. | sell | 5,172 |
| Sep 22, 26 | Keyes Jeffry R. | sell | 2,493 |
| Sep 21, 26 | LaPointe Christian | sell | 9,795 |
| Sep 22, 26 | LaPointe Christian | sell | 4,721 |
| Jun 22, 26 | LaPointe Christian | sell | 7,794 |
| Jun 23, 26 | LaPointe Christian | sell | 7,794 |
| Jun 22, 26 | Keyes Jeffry R. | sell | 4,116 |
| Jun 23, 26 | Keyes Jeffry R. | sell | 4,117 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QSI coverage
Recent articles, reports, and earnings notes.
No research on QSI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QSI report →Quantum-Si Achieves Historic Milestone in Protein Sequencing with Single-Molecule Detection of All 20 Amino Acids on Proteus™
globenewswire.com · Nov 18
QUANTUM X AND EVEREST CLOUD PARTNER TO BRING QUANTUM AND AI COMPUTE TO SIX SOUTH ASIAN MARKETS
prnewswire.com · Nov 16
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 13
Quantum-Si Q3 Earnings Call Highlights
marketbeat.com · Nov 6
Quantum-Si incorporated (QSI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Quantum-Si Incorporated (QSI) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 5
Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 5
Head-To-Head Comparison: Quantum-Si (NASDAQ:QSI) vs. Quanterix (NASDAQ:QTRX)
defenseworld.net · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.